 Plaque psoriasis profoundly affects patients' quality of life, underscoring the need for timely and effective treatments. Although several biologics are available to treat psoriasis, determining the best treatment option is difficult as head-to-head comparisons of biologics are rare. To address that gap, researchers analyzed studies involving adults with moderate to severe psoriasis treated with the inhibitors of IL-17, IL-12-23, IL-23, or tumor necrosis factor. 34 phase 3 double-blind randomized controlled trials were included in the analysis, which represented 11 biologics approved for the treatment of moderate to severe psoriasis in adults. This study focused on response rates in the first 12 weeks of treatment because rapid skin clearance and quality of life improvement are important patient preferences in biologic treatment. Outcome measures included improvements of at least 75, 90, and 100% in the psoriasis area and severity index, or PASI, at 2, 4, 8, and 12 weeks of treatment, and a score of 0 to 1 on the Dermatology Life Quality Index, or DLQI, at week 12, indicating no impact of psoriasis on quality of life. A Bayesian network meta-analysis enabled inclusion of head-to-head and placebo-controlled studies. That allowed for direct and indirect comparisons of treatment effects between populations and across many interventions. The average response to each treatment was calculated versus placebo and represented as a Himalayan plot. On a Himalayan plot, drugs with the greatest estimated treatment effect lie farthest along the X-axis. High narrow curves indicate a high degree of certainty, whereas short wide curves indicate less certainty. For example, curve A represents a drug with a high certainty of an estimated low treatment effect. Compared with all other biologics, Ixochismab and Brodellumab showed more rapid treatment effects on Pasi-75 response rates over weeks 2, 4, and 8. At week 12, Ixochismab and Risenkismab had the most rapid treatment effects, with some overlap with other biologics. Similarly, Ixochismab and Brodellumab showed more rapid treatment effects on Pasi-90 response rates over weeks 2, 4, 8, and 12, resulting in the highest Pasi-90 response rates. Similar trends were observed in Pasi-100 response rates. Regarding quality of life, treatment effect on DLQI scores was greatest for Ixochismab, Brodellumab, and Sekikiniamab at week 12 with some overlap between these treatments. Notable limitations of this NMA study should be noted, including reliance on both direct and indirect comparisons, potential trial heterogeneity, imputation methods for missing data, exclusions of other important endpoints, and other notable limitations. Overall these findings suggest that Ixochismab and Brodellumab could provide the most rapid skin clearance and quality of life improvements versus other biologics for patients with moderate to severe psoriasis, including Sekikiniamab, an IL-17 antagonist, and inhibitors of IL-1223, IL-23, or TNF pathways. That's important because rapid skin improvements and feeling noticeably better quickly are critical to psoriasis therapy and rank among the highest priorities for patients. Fast effects are also tied to longer term outcomes, including skin improvement, quality of life, and reduction in itch. And considering individual patient needs along with physician goals may help improve adherence to and satisfaction with therapy for plaque psoriasis.